Spinal Cord Injury - Pipeline Review, H2 2017

  • ID: 4412871
  • Report
  • Region: Global
  • 200 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Athersys Inc
  • CSL Ltd
  • Kringle Pharma Inc
  • Neuralstem Inc
  • RDD Pharma Ltd
  • MORE

Spinal Cord Injury - Pipeline Review, H2 2017

Summary

Our latest Pharmaceutical and Healthcare disease pipeline guide Spinal Cord Injury - Pipeline Review, H2 2017, provides an overview of the Spinal Cord Injury (Central Nervous System) pipeline landscape.

Spinal cord injury (SCI) is defined as damage or trauma caused to the spinal cord. SCI can lead to loss or impaired function resulting in reduced mobility or feeling. It is usually caused by trauma, transverse myelitis, polio, spina bifida or Friedreich's ataxia. Signs and symptoms of spinal cord injury include extreme back pain or pressure in the neck, head or back, paralysis in any part of the body, numbness, tingling or loss of sensation in the hands, fingers, feet or toes, loss of bladder or bowel control, difficulty in walking and impaired breathing after injury.

Report Highlights

Our Pharmaceutical and Healthcare latest pipeline guide Spinal Cord Injury - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Spinal Cord Injury (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Spinal Cord Injury (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Spinal Cord Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 9, 8, 1, 29 and 6 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 15 and 2 molecules, respectively.

Spinal Cord Injury (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Spinal Cord Injury (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Spinal Cord Injury (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Spinal Cord Injury (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Spinal Cord Injury (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Spinal Cord Injury (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Spinal Cord Injury (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Spinal Cord Injury (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Athersys Inc
  • CSL Ltd
  • Kringle Pharma Inc
  • Neuralstem Inc
  • RDD Pharma Ltd
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Spinal Cord Injury - Overview

Spinal Cord Injury - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Spinal Cord Injury - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Spinal Cord Injury - Companies Involved in Therapeutics Development

AbbVie Inc

Acorda Therapeutics Inc

Aevi Genomic Medicine Inc

Apollo Endosurgery Inc

Asterias Biotherapeutics Inc

Athersys Inc

BioArctic AB

BioAxone BioSciences Inc

Biogen Inc

CSL Ltd

CSPC Pharmaceutical Group Limited

Genervon Biopharmaceuticals LLC

Hemostemix Inc

Histocell SL

K-Stemcell Co Ltd

Kadimastem Ltd

Kringle Pharma Inc

MandalMed Inc

Mapreg SAS

Neuralstem Inc

Neuronax SAS

New World Laboratories Inc

Pharmicell Co Ltd

PixarBio Corp

RDD Pharma Ltd

RespireRx Pharmaceuticals Inc

SanBio Inc

Spectrum Pharmaceuticals Inc

Stemedica Cell Technologies Inc

TissueGene Inc

Tumorend LLC

Vertex Pharmaceuticals Inc

Vicore Pharma AB

Spinal Cord Injury - Drug Profiles

ABT-555 - Drug Profile

APO-1 - Drug Profile

ASTOPC-1 - Drug Profile

AX-007 - Drug Profile

BA-277 - Drug Profile

BA-434 - Drug Profile

C-21 - Drug Profile

Cell Therapy for Spinal Cord Injury - Drug Profile

Cell Therapy to Activate hNT-3 for Spinal Cord and Traumatic Brain Injury - Drug Profile

Cellgram-SCI - Drug Profile

CHEC-9 - Drug Profile

chondroitinase ABC nanosphere - Drug Profile

CLR-01 - Drug Profile

CM-101 - Drug Profile

CX-1739 - Drug Profile

CX-717 - Drug Profile

Drug for Spinal Cord Injury - Drug Profile

Drugs to Inhibit ROCK for Spinal Cord Injury - Drug Profile

ES-135 - Drug Profile

Fusion Protein to Antagonize EPHA4 for Amyotrophic Lateral Sclerosis, Acute Spinal Cord Injury, Sepsis and Ischemia Reperfusion Injury - Drug Profile

Gene Therapy for Spinal Cord Injury and Neurodegenerative Diseases - Drug Profile

glyburide - Drug Profile

GM-603 - Drug Profile

HBN-1 - Drug Profile

HC-016 - Drug Profile

ICCN-100 - Drug Profile

immune globulin (human) - Drug Profile

IMS-001 - Drug Profile

IMS-002 - Drug Profile

JM-4 - Drug Profile

KP-100IT - Drug Profile

laflunimus - Drug Profile

LM-11A31BHS - Drug Profile

LPA-181 - Drug Profile

Lpathomab - Drug Profile

MAP-4343 - Drug Profile

Monoclonal Antibody to Inhibit Connexin 43 for Spinal Cord Injury - Drug Profile

NCP-01 - Drug Profile

Neu-2000 - Drug Profile

NeuroRelease SCI - Drug Profile

neurovitas - Drug Profile

NgR(310)ecto-Fc - Drug Profile

NOVO-117 - Drug Profile

NSI-566 - Drug Profile

NWL-53 - Drug Profile

NX-210 - Drug Profile

Oligonucleotide for Central Nervous System and Metabolic Disorders - Drug Profile

oxymetazoline hydrochloride - Drug Profile

Peptide to Inhibit CSPG for Spinal Cord Injury and Neurodegenerative Diseases - Drug Profile

PF-05285401 - Drug Profile

Proteins to Activate BGLAP for Spinal Cord Injury and Autoimmune Disorders - Drug Profile

Q-Cells - Drug Profile

R-801 - Drug Profile

Recombinant Chondroitinase to Inhibit Chondroitin Sulfate Proteoglycan for Spinal Cord Injury and Brain Injury - Drug Profile

SB-618 - Drug Profile

SB-623 - Drug Profile

SC-0806 - Drug Profile

Small Molecules for Spinal Cord Injury - Drug Profile

Small Molecules to Block Voltage-Gated Potassium Channel for Spinal Cord Injury and Multiple Sclerosis - Drug Profile

SPI-1620 - Drug Profile

Stem Cell Therapy for Central Nervous System Disorders - Drug Profile

Stem Cell Therapy for Neurodegenerative Diseases - Drug Profile

Stem Cell Therapy for Spinal Cord Injury - Drug Profile

Stem Cell Therapy for Spinal Cord Injury - Drug Profile

Stem Cell Therapy for Spinal Cord Injury, Alzheimer's Disease, Progressive Supranuclear Palsy and Cerebral Palsy - Drug Profile

Synthetic Peptide to Antagonize PTPRS for Spinal Cord Injury - Drug Profile

Synthetic Peptides to Activate SDF-1 Alpha for CNS Disorders and Infectious Disease - Drug Profile

TG-N - Drug Profile

UH-0113 - Drug Profile

UH-0213 - Drug Profile

VX-210 - Drug Profile

Xcel-hNu - Drug Profile

Xcel-hNuP - Drug Profile

Spinal Cord Injury - Dormant Projects

Spinal Cord Injury - Discontinued Products

Spinal Cord Injury - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Spinal Cord Injury, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Spinal Cord Injury - Pipeline by AbbVie Inc, H2 2017

Spinal Cord Injury - Pipeline by Acorda Therapeutics Inc, H2 2017

Spinal Cord Injury - Pipeline by Aevi Genomic Medicine Inc, H2 2017

Spinal Cord Injury - Pipeline by Apollo Endosurgery Inc, H2 2017

Spinal Cord Injury - Pipeline by Asterias Biotherapeutics Inc, H2 2017

Spinal Cord Injury - Pipeline by Athersys Inc, H2 2017

Spinal Cord Injury - Pipeline by BioArctic AB, H2 2017

Spinal Cord Injury - Pipeline by BioAxone BioSciences Inc, H2 2017

Spinal Cord Injury - Pipeline by Biogen Inc, H2 2017

Spinal Cord Injury - Pipeline by CSL Ltd, H2 2017

Spinal Cord Injury - Pipeline by CSPC Pharmaceutical Group Limited, H2 2017

Spinal Cord Injury - Pipeline by Genervon Biopharmaceuticals LLC, H2 2017

Spinal Cord Injury - Pipeline by Hemostemix Inc, H2 2017

Spinal Cord Injury - Pipeline by Histocell SL, H2 2017

Spinal Cord Injury - Pipeline by K-Stemcell Co Ltd, H2 2017

Spinal Cord Injury - Pipeline by Kadimastem Ltd, H2 2017

Spinal Cord Injury - Pipeline by Kringle Pharma Inc, H2 2017

Spinal Cord Injury - Pipeline by MandalMed Inc, H2 2017

Spinal Cord Injury - Pipeline by Mapreg SAS, H2 2017

Spinal Cord Injury - Pipeline by Neuralstem Inc, H2 2017

Spinal Cord Injury - Pipeline by Neuronax SAS, H2 2017

Spinal Cord Injury - Pipeline by New World Laboratories Inc, H2 2017

Spinal Cord Injury - Pipeline by Pharmicell Co Ltd, H2 2017

Spinal Cord Injury - Pipeline by PixarBio Corp, H2 2017

Spinal Cord Injury - Pipeline by RDD Pharma Ltd, H2 2017

Spinal Cord Injury - Pipeline by RespireRx Pharmaceuticals Inc, H2 2017

Spinal Cord Injury - Pipeline by SanBio Inc, H2 2017

Spinal Cord Injury - Pipeline by Spectrum Pharmaceuticals Inc, H2 2017

Spinal Cord Injury - Pipeline by Stemedica Cell Technologies Inc, H2 2017

Spinal Cord Injury - Pipeline by TissueGene Inc, H2 2017

Spinal Cord Injury - Pipeline by Tumorend LLC, H2 2017

Spinal Cord Injury - Pipeline by Vertex Pharmaceuticals Inc, H2 2017

Spinal Cord Injury - Pipeline by Vicore Pharma AB, H2 2017

Spinal Cord Injury - Dormant Projects, H2 2017

Spinal Cord Injury - Dormant Projects, H2 2017 (Contd..1), H2 2017

Spinal Cord Injury - Dormant Projects, H2 2017 (Contd..2), H2 2017

Spinal Cord Injury - Dormant Projects, H2 2017 (Contd..3), H2 2017

Spinal Cord Injury - Discontinued Products, H2 2017

List of Figures

Number of Products under Development for Spinal Cord Injury, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AbbVie Inc
  • Acorda Therapeutics Inc
  • Aevi Genomic Medicine Inc
  • Apollo Endosurgery Inc
  • Asterias Biotherapeutics Inc
  • Athersys Inc
  • BioArctic AB
  • BioAxone BioSciences Inc
  • Biogen Inc
  • CSL Ltd
  • CSPC Pharmaceutical Group Limited
  • Genervon Biopharmaceuticals LLC
  • Hemostemix Inc
  • Histocell SL
  • K-Stemcell Co Ltd
  • Kadimastem Ltd
  • Kringle Pharma Inc
  • MandalMed Inc
  • Mapreg SAS
  • Neuralstem Inc
  • Neuronax SAS
  • New World Laboratories Inc
  • Pharmicell Co Ltd
  • PixarBio Corp
  • RDD Pharma Ltd
  • RespireRx Pharmaceuticals Inc
  • SanBio Inc
  • Spectrum Pharmaceuticals Inc
  • Stemedica Cell Technologies Inc
  • TissueGene Inc
  • Tumorend LLC
  • Vertex Pharmaceuticals Inc
  • Vicore Pharma AB
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll